Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)

  • STATUS
    Recruiting
  • days left to enroll
    72
  • participants needed
    20
  • sponsor
    University Health Network, Toronto
Updated on 7 May 2021
cancer
cavities
pembrolizumab
nivolumab
head and neck cancer
neck cancer
metastatic head and neck cancer

Summary

This study aims to study the kinetics of ctDNA levels after the first dose of immune checkpoint inhibitor in patients with recurrent or metastatic head and neck cancer. This is an important study to understand the optimal timing for ctDNA quantitation for future studies in immunotherapy, though further validation would be needed in other tumor types. It may help standardize the most relevant blood collection time points so that patients will not be subjected to multiple blood draws at random time points in future liquid biopsy trials.

Details
Condition Metastasis, Bone Metastases, Metastatic Cancer, Brain Metastases, Liver Metastases, Neoplasm Metastasis, Carcinoma, Vulvar Dysplasia and Carcinoma, Advanced Malignancies, Squamous cell carcinoma, Squamous cell carcinoma, head and neck cancer, head and neck cancer, Vulvar Dysplasia and Carcinoma, Liver Metastases, Bone Metastases, Advanced Cancer, Squamous Cell Carcinoma of the Head and Neck, Brain Metastases, Squamous Cell Carcinoma of Head and Neck, Advanced Malignancies, HNSCC, Cancer, Metastatic, Metastatic Cancer, Neoplasm Metastasis, cancer advanced, cancer of the head and neck, cancers metastatic, epidermoid carcinoma, squamous cell cancer, metastases, metastatic disease, secondary cancer, secondaries, metastatic tumor, metastasized
Clinical Study IdentifierNCT04606940
SponsorUniversity Health Network, Toronto
Last Modified on7 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically or cytological confirmed recurrent, metastatic or advanced HNSCC of the oral cavity, oropharynx, hypopharynx, larynx or unknown origin (but being treated as HNSCC)
Availability of tumor sample
Patients who are going to receive at least one dose of anti-PD1antibody (nivolumab or pembrolizumab)

Exclusion Criteria

Nasopharynx, maxillary sinus, nasal/nasal vestibule squamous tumors
Patients who are receiving concomitantly any other tumor-specific treatment (chemotherapy, radiotherapy, any monoclonal antibodies different from anti- PD-1 antibodies)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note